ReviewTransfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie2026
Blood Pharming of Red Cells.
Review in Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The transfusion of blood is an indispensable and irreplaceable component of contemporary medicine. Nevertheless, particularly in patients with very rare blood groups, the lack of blood products still represents a significant health problem on a global scale. In order to address this shortage, strategies for producing artificial blood substitutes have been pursued for a period of time exceeding 60 years. Summary: This overview synthesizes the latest advancements in the field of erythropoiesis, encompassing the expansion strategies for erythrocyte cells, the diverse sources of ex vivo-expanded erythrocytes, the impediments to clinical implementation, the prospective applications, and alternative blood products. Conclusions: Ex vivo generation of red blood cells (RBCs) has advanced from proof-of-concept to early clinical testing, yet scalable, cost-effective manufacturing remains unresolved. Continued optimization of cell sources, immortalized progenitor lines, and bioreactor technologies, alongside deeper mechanistic insights into terminal erythropoiesis and enucleation, will be key. Integrating these advances within rigorous regulatory frameworks could ultimately enable standardized, universally compatible RBC products.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.